^
Association details:
Biomarker:ESRP1-RAF1 fusion
Cancer:Prostate Cancer
Drug:U0126 (MEK1 inhibitor, MEK2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

Excerpt:
We also observed a dramatic increase in cell invasion in RWPE cells expressing either SLC45A3-BRAF or ESRP1-RAF1, which was sensitive to sorafenib or the MEK inhibitor U0126.
DOI:
10.1038/nm.2166